Publications by authors named "Brigitte Demers"

Claim this Profile
S
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study.
Joaquina C Baranda, Debbie Robbrecht, Ryan Sullivan, Bernard Doger, Armando Santoro, Brigitte Demers

Clin Transl Sci· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.
Debbie Robbrecht, Jean-Jacques Grob, Oliver Bechter, Matteo Simonelli, Bernard Doger, Brigitte Demers

Clin Transl Sci· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape.
Anne-Marie Lefebvre, Julien Adam, Céline Nicolazzi, Christelle Larois, Florence Attenot, Brigitte Demers

Lung Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.
Vincent A de Weger, Maja de Jonge, Marlies H G Langenberg, Jan H M Schellens, Martijn Lolkema, Brigitte Demers

Br J Cancer· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors.
Philippe L Bédard, Michael A Davies, Scott Kopetz, Dejan Juric, Geoffrey I Shapiro, Brigitte Demers

Cancer· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.
Sylvia Julien, Ana Merino-Trigo, Ludovic Lacroix, Marc Pocard, Diane Goéré, Brigitte Demers

Clin Cancer Res· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography.
Sonia Lavisse, Pascale Lejeune, Valérie Rouffiac, Nicolas Elie, Estelle Bribes, Brigitte Demers

Invest Radiol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A secreted anti-activator, OspD1, and its chaperone, Spa15, are involved in the control of transcription by the type III secretion apparatus activity in Shigella flexneri.
Claude Parsot, Elisabeth Ageron, Christophe Penno, Maria Mavris, Kais Jamoussi, Brigitte Demers

Mol Microbiol· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulation of transcription by the activity of the Shigella flexneri type III secretion apparatus.
Maria Mavris, Anne-Laure Page, Régis Tournebize, Brigitte Demers, Philippe Sansonetti

Mol Microbiol· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis